Translating G9a epigenetics' role: From cell machinery to cancer therapy

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Aberrant epigenetic modifications, including abnormal histone methylation, are critical in cancer development.
• The histone methyltransferase G9a is a key enzyme implicated in oncogenic signaling pathways and tumor progression.
• G9a's dual role involves silencing tumor suppressor genes and methylating non-histone proteins, promoting a mesenchymal and stem-cell-like phenotype and drug resistance.

Purpose of the Study:

• To provide a comprehensive overview of G9a's epigenetic role in cancer, with a specific focus on prostate cancer (PCa).
• To highlight the current research status and therapeutic potential of G9a-targeted therapies.
• To identify context-specific roles of G9a across tumor types for potential therapeutic vulnerabilities.

Main Methods:

• Literature review of G9a's function in cancer, particularly PCa.
• Analysis of molecular networks altered by G9a hyperactivation.
• Examination of current research on G9a inhibitors and targeted therapies.

Main Results:

• G9a plays a significant role in cancer development, progression, and drug resistance.
• G9a's specific molecular targets and networks in PCa require further elucidation.
• Progress has been made in understanding G9a's mechanisms, but context-specific roles remain a challenge.

Conclusions:

• Elucidating G9a's context-specific roles is crucial for identifying tumor vulnerabilities.
• Targeted therapies incorporating G9a inhibitors show potential for enhancing clinical outcomes in cancer treatment.
• Further research is needed to fully leverage G9a as a therapeutic target in oncology.